Method of diagnosing cartilage tissue abnormalities
US4704356A · kind A · utility
30Cited by
0References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 27, 1984 |
| Grant date | Nov 3, 1987 |
| Priority date | — |
| Expiry date | Mar 27, 2004 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/815
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
It is found that abnormal levels of keratan sulfate in the peripheral blood are indicative of abnormalities of cartilage or cartilage-like tissues. Specifically, elevated levels of keratan sulfate in the peripheral blood plasma or serum are indicative of osteoarthritis and either substantially complete absence of or very elevated levels of keratan sulfate in the peripheral blood are indicative of muscular dystrophy and related disorders. The level of keratan sulfate in the peripheral blood is determined by an immunoassay using a monoclonal antibody. Preferably the immunoassay employs a colorimetric reporter system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.